NCT06987058View on ClinicalTrials.gov

RVU120 Rollover Study

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 15, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
Advanced Solid TumorsAcute Myeloid Leukaemia (AML)High-risk Myelodysplastic Syndrome
Interventions
DRUG

RVU120

RVU120 is a potent, selective inhibitor of CDK8 and its paralog CDK19

Trial Locations (2)

31008

Clinica Universidad de Navarra, Pamplona

80-214

Uniwersyteckie Centrum Kliniczne, Gdansk

All Listed Sponsors
lead

Ryvu Therapeutics SA

INDUSTRY